Bobby Q. Lanier

4.8k total citations · 2 hit papers
31 papers, 3.4k citations indexed

About

Bobby Q. Lanier is a scholar working on Physiology, Immunology and Allergy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bobby Q. Lanier has authored 31 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Physiology, 19 papers in Immunology and Allergy and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bobby Q. Lanier's work include Asthma and respiratory diseases (24 papers), Allergic Rhinitis and Sensitization (19 papers) and Respiratory and Cough-Related Research (8 papers). Bobby Q. Lanier is often cited by papers focused on Asthma and respiratory diseases (24 papers), Allergic Rhinitis and Sensitization (19 papers) and Respiratory and Cough-Related Research (8 papers). Bobby Q. Lanier collaborates with scholars based in United States, Canada and Argentina. Bobby Q. Lanier's co-authors include Angel FowlerTaylor, Jonathan Corren, Niroo Gupta, Thomas A.E. Platts‐Mills, C. Motala, Thomas Bieber, Johannes Ring, Ronald Dahl, William W. Busse and Richard F. Lockey and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Clinical & Experimental Allergy and Otolaryngology.

In The Last Decade

Bobby Q. Lanier

29 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003

2004 1.6k citations S. G. O. Johansson, Thomas Bieber et al. Journal of Allergy and Clinical Immunology profile →
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

2001 978 citations William W. Busse, Jonathan Corren et al. Journal of Allergy and Clinical Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bobby Q. Lanier United States	16	2.2k	2.1k	933	818	411	31	3.4k
Ioana Agache Romania	34	1.9k 0.8×	2.5k 1.2×	903 1.0×	708 0.9×	803 2.0×	128	4.0k
Stanley M. Fìneman United States	23	2.2k 1.0×	1.6k 0.8×	507 0.5×	622 0.8×	189 0.5×	58	3.0k
Dana Wallace United States	24	3.5k 1.6×	2.2k 1.0×	454 0.5×	1.6k 1.9×	335 0.8×	53	4.8k
Mark S. Dykewicz United States	27	2.3k 1.0×	2.0k 1.0×	619 0.7×	597 0.7×	211 0.5×	72	3.4k
Louis M. Mendelson United States	21	1.8k 0.8×	882 0.4×	525 0.6×	722 0.9×	169 0.4×	43	2.6k
M. L. Kowalski Poland	10	1.6k 0.7×	1.1k 0.5×	327 0.4×	656 0.8×	247 0.6×	20	2.4k
Guy A. Settipane United States	34	2.2k 1.0×	2.0k 1.0×	937 1.0×	457 0.6×	202 0.5×	96	3.7k
Kathleen E. Harris United States	30	1.4k 0.6×	1.4k 0.7×	527 0.6×	299 0.4×	556 1.4×	105	3.3k
Roy Gerth van Wijk Netherlands	39	4.3k 2.0×	3.0k 1.5×	864 0.9×	1.9k 2.4×	261 0.6×	165	5.5k
Maria Beatrice Bilò Italy	28	3.2k 1.4×	956 0.5×	193 0.2×	1.1k 1.4×	427 1.0×	106	3.9k

Countries citing papers authored by Bobby Q. Lanier

Since Specialization

Citations

This map shows the geographic impact of Bobby Q. Lanier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bobby Q. Lanier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bobby Q. Lanier more than expected).

Fields of papers citing papers by Bobby Q. Lanier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bobby Q. Lanier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bobby Q. Lanier. The network helps show where Bobby Q. Lanier may publish in the future.

Co-authorship network of co-authors of Bobby Q. Lanier

This figure shows the co-authorship network connecting the top 25 collaborators of Bobby Q. Lanier. A scholar is included among the top collaborators of Bobby Q. Lanier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bobby Q. Lanier. Bobby Q. Lanier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yin, Wenjie, Yaming Xue, Bobby Q. Lanier, et al.. (2018). Clinical implications of CD4+ T cell subsets in adult atopic asthma patients. Allergy Asthma and Clinical Immunology. 14(1). 7–7. 10 indexed citations

Lanier, Bobby Q., et al.. (2018). Successful long-term, adjunctive use of guaifenesin in a patient with a complex atopic medical history and primary immune deficiency: A case report. Respiratory Medicine Case Reports. 25. 145–146. 1 indexed citations

Sullivan, Patrick W., Vahram Ghushchyan, Prakash Navaratnam, et al.. (2017). National Prevalence of Poor Asthma Control and Associated Outcomes Among School-Aged Children in the United States. The Journal of Allergy and Clinical Immunology In Practice. 6(2). 536–544.e1. 36 indexed citations

Nolte, Hendrik, Niran J. Amar, David I. Bernstein, et al.. (2014). Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Annals of Allergy Asthma & Immunology. 113(1). 93–100.e3. 41 indexed citations

Bernstein, David I., Michael S. Blaiss, Linda Cox, et al.. (2011). Current standards and future directions in immunotherapy: perspectives on challenges and opportunities for the allergist. Annals of Allergy Asthma & Immunology. 107(5). 422–425. 1 indexed citations

Prenner, Bruce M., Bobby Q. Lanier, David I. Bernstein, Tulin Shekar, & Ariel Teper. (2010). Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 125(6). 1247–1253.e5. 26 indexed citations

Prenner, Bruce M., Bobby Q. Lanier, David I. Bernstein, Tulin Shekar, & Ariel Teper. (2010). Reply. Journal of Allergy and Clinical Immunology. 127(1). 289–289. 1 indexed citations

Berger, William E., Anjuli Nayak, Bobby Q. Lanier, et al.. (2008). Efficacy and Safety of Once-Daily Ciclesonide Nasal Spray in Children With Allergic Rhinitis. Pediatric Asthma Allergy & Immunology. 21(2). 73–82. 9 indexed citations

Pawankar, Ruby, Carlos E. Baena‐Cagnani, Jean Bousquet, et al.. (2008). State of World Allergy Report 2008: Allergy and Chronic Respiratory Diseases. World Allergy Organization Journal. 1. S4–S17. 43 indexed citations

10.

Pawankar, Ruby, Carlos E. Baena‐Cagnani, Jean Bousquet, et al.. (2008). State of World Allergy Report 2008. World Allergy Organization Journal. 1(Supplement). S4–S17. 75 indexed citations

11.

Lanier, Bobby Q. & Anjuli Nayak. (2008). Prevalence and Impact of Nighttime Symptoms in Adults and Children With Asthma: A Survey. Postgraduate Medicine. 120(4). 58–66. 9 indexed citations

12.

Marple, Bradley F., John A. Fornadley, Alpen A. Patel, et al.. (2007). Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngology. 136(S6). S107–24. 117 indexed citations

13.

Lanier, Bobby Q., Kai Guan, Bradley F. Marple, & G. Michael Wall. (2007). Pathophysiology and progression of nasal septal perforation. Annals of Allergy Asthma & Immunology. 99(6). 473–480. 75 indexed citations

14.

Johansson, S. G. O., Thomas Bieber, Ronald Dahl, et al.. (2004). Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy and Clinical Immunology. 113(5). 832–836. 1588 indexed citations breakdown →

15.

Lanier, Bobby Q., et al.. (2004). Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Current Medical Research and Opinion. 20(8). 1227–1233. 34 indexed citations

16.

Lanier, Bobby Q.. (2003). Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE. Annals of Allergy Asthma & Immunology. 90(6). 13–15. 12 indexed citations

17.

Lanier, Bobby Q., Jonathan Corren, William R. Lumry, et al.. (2003). Omalizumab is effective in the long-term control of severe allergic asthma. Annals of Allergy Asthma & Immunology. 91(2). 154–159. 149 indexed citations

18.

Busse, William W., Jonathan Corren, Bobby Q. Lanier, et al.. (2002). Omalizumab improves asthma-specific quality of life (QoL): An analysis of data from 1071 patients. Journal of Allergy and Clinical Immunology. 109(1). S291–S291. 1 indexed citations

19.

Lanier, Bobby Q., et al.. (2001). Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Annals of Allergy Asthma & Immunology. 86(6). 641–648. 23 indexed citations

20.

Busse, William W., Jonathan Corren, Bobby Q. Lanier, et al.. (2001). Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of Allergy and Clinical Immunology. 108(2). 184–190. 978 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact